چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | علی ایمانی |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | دانشکده مدیریت و اطلاع رسانی پزشکی |
| کد مقاله | 59874 |
| عنوان فارسی مقاله | COMPARING THE COST-EFFECTIVENESS OF AVONEX AND BETAFERON IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN IRAN |
| عنوان لاتین مقاله | COMPARING THE COST-EFFECTIVENESS OF AVONEX AND BETAFERON IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN IRAN |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | ISPOR 14TH Annual European Congress Research Abstracts |
| نوع کنگره / همایش | وب پوستر |
| کشور محل برگزاری کنگره/ همایش | |
| شهر محل برگزاری کنگره/ همایش | Madrid |
| سال انتشار/ ارائه شمسی | 1390 |
| سال انتشار/ارائه میلادی | 2011 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1390/10/22 الی 1390/10/25 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | http://www.valueinhealthjournal.com/article/S1098-3015%2811%2902057-2/fulltext |
| آدرس علمی (Affiliation) نویسنده متقاضی | Tabriz University of Medical sciences , Tabriz, Iran |
| نویسنده | نفر چندم مقاله |
|---|---|
| علی ایمانی | اول |
| مینا گلستانی | دوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Objectives Multiple sclerosis (MS) is the neurologic disability that can dramatically affect the quality of life (QoL) of patients and their families. Family life, economic status, and social interaction may be affected by somatic symptoms of the disease. Approximately 70,000 people in the Islamic Republic of Iran are affected by MS. Under budgetary constraints,Cost-effectiveness and cost-utility analyses (CEA/CUAs) are useful tools to assess the tradeoff between the added costs and potential benefits (e.g., improved patient outcomes) of new therapies. Methods The primary objective of this analysis was to evaluate the cost-effectiveness of Avonex compared with Betaferon from the Iranian Ministry of Health(MoH) over a 2-year time horizon. The relative risk reduction (RRR) method was used to compare reduction in relapse rates and disease progression data from pivotal randomized double-blind placebo-controlled clinical trials of the DMDs. The evaluation was conducted from the perspective of a Iranian health care sector (direct medical costs and indirect cost considered). The primary economic endpoint was cost per relapse avoided . Costs and outcomes occurring in the second year were discounted 3% to bring to 2010 present values. One way sensitivity analyses were conducted on key input variables to assess their impact on cost per relapse avoided. Results The 2-year reductions in clinical relapses for treatment with Avonex,Betaferon were 0.69 and 0.60 relatively. In the base case analysis, Avonex had the most favorable costs per relapse avoided (2652778 Rials) rather than Betaferon. Sensitivity analyses showed that these results were robust to changes in key input parameters, such as the number of relapses and disease progression steps in untreated patients, the progression rates, the average cost of relapse. Conclusions This evaluation suggests that IFN β-1a SC injection(Avonex) represent the most cost-effective DMDs for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse avoided,rather than Bataferon. |
| کلمات کلیدی |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| PND29.pdf | 1395/10/27 | 60078 | دانلود |
| PND 29.png | 1395/10/27 | 645754 | دانلود |
